Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Cancer Res. 2020 Sep 30;80(23):5380–5392. doi: 10.1158/0008-5472.CAN-20-1439

Figure 5. Combined PI3K/mTOR and CHK1 inhibition mitigates RAD51-mediated HR repair in HGSOC cells.

Figure 5.

A, Combination of CHK1 and PI3K/mTOR pathway inhibitors attenuated homologous recombination (HR) repair activity in a DRGFP reporter assay in both OVCAR8 and PEO1 cells. GFP-positive cells were analyzed by flow cytometry. B, Cells were treated with prexasertib (Prex, 5 nM) and/or LY3023414 (LY302, 200 nM) following the PARP inhibitor olaparib (5 μM) treatment for 48 hours. Immunofluorescence staining of RAD51 foci (green) was conducted for HR repair activity. Representative images were taken at x 63 magnification and scale bar is 20 μm (up). Cells with ≥ 5 RAD51 foci were counted as RAD51+ cells and the percentage of RAD51+ cells is plotted (bottom). All data are shown as mean ± SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001.